Now Accepting Late Breaking Trials, Novel Technology, and Emerging Studies!Â
Deadline: November 8, 2024 at 5:00pm Eastern Time
Submission Deadline: November 8, 2024
1. Late Breaking Trials – Abstracts of clinical trials that will present results of prospective studies, preferably multicenter (5 centers or more). Trials that are ongoing but expect to have results at the time of presentation are allowed. Specification of the number of patients or procedures expected to be reported on and the outcomes that will be presented should be included in the abstract. Priority will be given to abstracts that contain preliminary data.
2. Novel Technology and Emerging Studies – Abstracts of ongoing trials that do not have results and are not expected to present data during Venous 2025. Novel technology that is in development is allowed. Abstract of novel technology should contain the indications for use and the mechanism of action. Abstracts of emerging studies should describe in details patient recruitment plan, projected enrollment, indications, inclusion and exclusion criteria. Priority will be given to clinical trials in the first year of enrollment and technology that is in early commercialization phase.
Kindly note that retrospective analyses and studies that do not meet these criteria will not be considered as they have already been evaluated during the regular abstract submission process. These sessions will bring the best and latest science to VENOUS2025.
For questions regarding the AVF 37th Annual Meeting, contact AVF at 855-836-6871 or [email protected]
Submission Deadline: November 8, 2024 at 5:00pm Eastern Time
